Cargando…
Long‐acting and extended‐release implant and nanoformulations with a synergistic antiretroviral two‐drug combination controls HIV‐1 infection in a humanized mouse model
The HIV pandemic has affected over 38 million people worldwide with close to 26 million currently accessing antiretroviral therapy (ART). A major challenge in the long‐term treatment of HIV‐1 infection is nonadherence to ART. Long‐acting antiretroviral (LA‐ARV) formulations, that reduce dosing frequ...
Autores principales: | Beloor, Jagadish, Kudalkar, Shalley N., Buzzelli, Gina, Yang, Fan, Mandl, Hanna K., Rajashekar, Jyothi K., Spasov, Krasimir A., Jorgensen, William L., Saltzman, W. Mark, Anderson, Karen S., Kumar, Priti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780078/ https://www.ncbi.nlm.nih.gov/pubmed/35079625 http://dx.doi.org/10.1002/btm2.10237 |
Ejemplares similares
-
Creation of a long-acting nanoformulated dolutegravir
por: Sillman, Brady, et al.
Publicado: (2018) -
Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages
por: Araínga, Mariluz, et al.
Publicado: (2015) -
Potent Noncovalent Inhibitors of the Main Protease
of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel
Guided by Free Energy Perturbation Calculations
por: Zhang, Chun-Hui, et al.
Publicado: (2021) -
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations
por: Balkundi, Shantanu, et al.
Publicado: (2011) -
Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy
por: Martinez-Skinner, Andrea L., et al.
Publicado: (2015)